4.Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art
Celeste SILVEIRA ; Renato GUEDES ; Diana MAIA ; Rosário CURRAL ; Rui COELHO
Psychiatry Investigation 2019;16(12):877-888
Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients’ quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain’s lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals’ well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities.
Anxiety Disorders
;
Bipolar Disorder
;
Cognition
;
Cognition Disorders
;
Comorbidity
;
Depression
;
Diagnosis
;
Drug Therapy
;
Fatigue
;
Humans
;
Learning
;
Memory
;
Multiple Sclerosis
;
Neuroimaging
;
Personality Disorders
;
Prevalence
;
Psychotic Disorders
;
Quality of Life
;
Suicide
5.Initial Seizure Threshold in Brief-Pulse Bilateral Electroconvulsive Therapy in Patients with Schizophrenia or Schizoaffective Disorder
Seong Hoon JEONG ; Tak YOUN ; Younsuk LEE ; Jin Hyeok JANG ; Young Wook JEONG ; Yong Sik KIM ; In Won CHUNG
Psychiatry Investigation 2019;16(9):704-712
OBJECTIVE: The present study aimed to report the initial seizure threshold (IST) of a brief-pulse bilateral electroconvulsive therapy (BP-BL ECT) in Korean patients with schizophrenia/schizoaffective disorder and to identify IST predictors. METHODS: Among 67 patients who received ECT and diagnosed with schizophrenia/schizoaffective disorder based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, we included 56 patients who received 1-millisecond BP-BL ECT after anesthesia with sodium thiopental between March 2012 and June 2018. Demographic and clinical information was gathered from electronic medical records, and a multiple regression analysis was conducted to identify predictors of the IST. RESULTS: The mean age of the patients was 36.9±12.0 years and 30 (53.6%) patients were male. The mean and median IST were 105.9±54.5 and 96 millicoulombs (mC), respectively. The IST was predicted by age, gender, and dose (mg/kg) of sodium thiopental. Other physical and clinical variables were not associated with the IST. CONCLUSION: The present study demonstrated that the IST of 1-ms BP-BL ECT following sodium thiopental anesthesia in Korean patients was comparable to those reported in previous literature. The IST was associated with age, gender, and dose of sodium thiopental.
Anesthesia
;
Diagnostic and Statistical Manual of Mental Disorders
;
Electroconvulsive Therapy
;
Electronic Health Records
;
Humans
;
Male
;
Psychotic Disorders
;
Schizophrenia
;
Seizures
;
Sodium
;
Thiopental
6.Acute kidney injury in pediatric patients with rhabdomyolysis.
Young Shin LIM ; Heeyeon CHO ; Sang Taek LEE ; Yeonhee LEE
Korean Journal of Pediatrics 2018;61(3):95-100
PURPOSE: This study aimed to evaluate the clinical findings in pediatric rhabdomyolysis and the predictive factors for acute kidney injury (AKI) in Korean children. METHODS: Medical records of 39 Korean children, who were newly diagnosed with rhabdomyolysis from January 2008 to December 2015, were retrospectively analyzed. The diagnosis was made from the medical history, elevated serum creatinine kinase level >1,000 IU/L, and plasma myoglobin level >150 ng/mL. Patients with muscular dystrophy and myocardial infarction were excluded. RESULTS: The median patient age at diagnosis was 14.0 years (range, 3–18 years), and the male to female ratio was 2.5. The most common presenting symptom was myalgia (n=25, 64.1%), and 14 patients (35.9%) had rhabdomyolysis-induced AKI. Eighteen patients (46.2%) had underlying diseases, such as epilepsy and psychotic disorders. Ten of these patients showed rhabdomyolysis-induced AKI. The common causes of rhabdomyolysis were infection (n=12, 30.7%), exercise (n=9, 23.1%), and trauma (n=8, 20.5%). There was no difference in the distribution of etiology between AKI and non-AKI groups. Five patients in the AKI group showed complete recovery of renal function after stopping renal replacement therapy. The median length of hospitalization was 7.0 days, and no mortality was reported. Compared with the non-AKI group, the AKI group showed higher levels of peak creatinine kinase and myoglobin, without statistical significance. CONCLUSION: The clinical characteristics of pediatric rhabdomyolysis differ from those observed in adult patients. Children with underlying diseases are more vulnerable to rhabdomyolysis-induced AKI. AKI more likely develops in the presence of a high degree of albuminuria.
Acute Kidney Injury*
;
Adult
;
Albuminuria
;
Child
;
Creatinine
;
Diagnosis
;
Epilepsy
;
Female
;
Hospitalization
;
Humans
;
Male
;
Medical Records
;
Mortality
;
Muscular Dystrophies
;
Myalgia
;
Myocardial Infarction
;
Myoglobin
;
Phosphotransferases
;
Plasma
;
Psychotic Disorders
;
Renal Replacement Therapy
;
Retrospective Studies
;
Rhabdomyolysis*
7.Development of Smartphone Application for Cognitive Behavioral Therapy-Based Case Management in Patients with Schizophrenia.
Sung Wan KIM ; Ga Young LEE ; Hye Young YU ; Ji Hyun PARK ; Yong Sung LEE ; Ju Wan KIM ; Cheol PARK ; Ju Yeon LEE ; Yo Han LEE ; Jae Min KIM ; Jin Sang YOON
Korean Journal of Schizophrenia Research 2016;19(1):10-16
OBJECTIVES: This article aims to describe the development of smartphone application for the case management of patients with schizophrenia. METHODS: Gwangju Bukgu-Community Mental Health Center developed and launched a smartphone application (HYM) for cognitive-behavioral case management and symptom monitoring. The development of the application involved psychiatrists, nurses, social workers, psychologists, and software technicians from a software development company (Goosl Corp.). RESULTS: The HYM application for clients includes six main modules including Thought record, Symptom record, Daily life record, Official notices, Communication, and Scales. The key module is the 'Thought Record' for self-directed cognitive-behavioral treatment (CBT). When the client writes and sends the self-CBT sheet to the case manager, the latter receives a notification and can provide feedback in real time. 'Communication' and 'Official notices' are useful for promoting communication between case managers and clients with schizophrenia. Ratings in 'Symptom record', 'Daily life record', and 'Scales' modules are stored in graphic or table form representing changes in them and shared with case managers. CONCLUSION: The interactive function of this application is the key characteristics that distinguishes it from other mobile self-treatment tools. This smartphone application may contribute to the development of a youth- and customer-friendly case management system for individuals with early psychosis.
Case Management*
;
Cognitive Therapy
;
Early Intervention (Education)
;
Gwangju
;
Humans
;
Mental Health
;
Psychiatry
;
Psychology
;
Psychotic Disorders
;
Schizophrenia*
;
Smartphone*
;
Social Work
;
Social Workers
;
Weights and Measures
8.Practice of Acute and Maintenance Electroconvulsive Therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013.
Melike Ceyhan Balci SENGUL ; Ayse Nur Inci KENAR ; Ezgi HANCI ; Ibrahim SENDUR ; Cem SENGUL ; Hasan HERKEN
Clinical Psychopharmacology and Neuroscience 2016;14(1):57-63
OBJECTIVE: Electroconvulsive therapy (ECT) can be given as the form of acute, continuation or maintenance ECT according to the process of administration. We report our 7 years' observation with acute and maintenance ECT in a university hospital in Turkey. METHODS: The medical records of the hospitalized patients treated with acute or maintenance ECT between the years 2007 and 2013 was retrospectively analyzed. The sociodemographic characteristics, diagnosis, data of ECT and the co-administered psychotropic drugs were recorded. The frequency of ECT was calculated by identifying the total number of the hospitalized patients during the study period from the hospital records. RESULTS: A total number of 1,432 female and 1,141 male patients hospitalized in a period of 7 years, with a total number of 111 patients treated with ECT. The ratio of ECT was 4%, maintenance/acute ECT 11%. For acute ECT, affective disorders (65.3%) and psychotic disorders (21.6%) were among the leading diagnoses. Maintenance ECT, the diagnosis was; 6 affective disorders, 4 psychotic disorders and 1 obsessive compulsive disorder. There was a significant difference between the patients receiving acute and maintenance ECT in terms of age, duration of illness, and number of previous hospitalizations and ECTs. CONCLUSION: The percentage of patients treated with acute ECT is lower in our institution than that in many other institutions from our country. Acute and maintenance ECT should be considered as an important treatment option particularly for patients with long disease duration, a high number of hospitalizations and a history of benefiting from previous ECTs.
Diagnosis
;
Electroconvulsive Therapy*
;
Female
;
Hospital Records
;
Hospitalization
;
Humans
;
Male
;
Medical Records
;
Mood Disorders
;
Obsessive-Compulsive Disorder
;
Psychotic Disorders
;
Psychotropic Drugs
;
Retrospective Studies
;
Turkey*
9.Understanding How Postnatal Depression Screening and Early Intervention Work in the Real World - A Singaporean Perspective.
Theresa My LEE ; Dianne BAUTISTA ; Helen Y CHEN
Annals of the Academy of Medicine, Singapore 2016;45(10):466-470
Postnatal depression is a major public health problem with clearly established adverse effects in child outcomes. This study examines the 4-year outcomes of a screening and early intervention programme, in relation to improvement in symptoms, functioning and health quality of life. Women were prospectively recruited up to 6 months postdelivery, using the Edinburgh Postnatal Depression Scale (EPDS) as a screening tool. High-scorers (EPDS >13), were offered psychiatric consultation, and those with borderline scores (EPDS 10-12) were provided counselling, and offered follow-up phone counselling by the assigned case manager. Outcome measures were obtained at baseline, and at 6 months or discharge if earlier, for levels of symptoms, functioning, and health quality of life. From 2008 to 2012, 5245 women were screened, with 307 (5.9%) women with EPDS >13 receiving intervention. Of these, 70.0% had depression, 4.6% anxiety and 3.4% psychosis. In the depression subgroup, the net change was improvement of 93.4% EPDS symptom scores, 92.2% Global Assessment of Functioning (GAF) scores, and 88.3% visual analogue scale (EQ VAS) health quality of life scores. Outcome scores across diagnostic categories demonstrated median changes of 10 points on EPDS, 20 points on GAF, and 25 points on EQ VAS, reflecting 73.9%, 36.4% and 41.7% change from baseline scores. Women with psychosis showed the biggest (80.0%) relative change in GAF functioning scores from baseline to discharge but had the lowest median change in EPDS symptom scores. A screening and intervention programme rightly-sited within an obstetric setting can improve clinical outcomes because of early detection and intervention.
Adult
;
Anxiety Disorders
;
diagnosis
;
therapy
;
Case Management
;
Counselors
;
Delivery of Health Care
;
Depression, Postpartum
;
diagnosis
;
therapy
;
Early Medical Intervention
;
Female
;
Health Status
;
Humans
;
Mass Screening
;
Obstetrics
;
Outcome Assessment (Health Care)
;
Prospective Studies
;
Psychiatry
;
Psychotic Disorders
;
diagnosis
;
therapy
;
Puerperal Disorders
;
diagnosis
;
therapy
;
Quality of Life
;
Referral and Consultation
;
Singapore
10.The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder.
Young Hoon KO ; Kyoung Sae NA ; Chul Eung KIM ; Seung Hyun KIM ; Yang Whan JEON ; Jung Seo YI ; Moon Soo LEE ; Shin Gyeom KIM ; Hyun Ghang JEONG ; Han Yong JUNG
Psychiatry Investigation 2014;11(4):459-466
OBJECTIVE: Switching antipsychotics is one useful therapeutic option when the treatment of schizophrenia encounters suboptimal efficacy and intolerability issues. This study aimed to investigate the efficacy and tolerability of cross-tapering switching to ziprasidone from other antipsychotics. METHODS: A total of 67 patients with schizophrenia or schizoaffective disorder were recruited in this 12-week, multicenter, non-comparative, open-label trial. Prior antipsychotics were allowed to be maintained for up to 4 weeks during the titration of ziprasidone. Efficacy was primarily measured using the 18-item Brief Psychotic Rating Scale (BPRS) at baseline, 4 weeks, 8 weeks, and 12 weeks. Efficacy was secondarily measured by the Clinical Global Impression-Severity (CGI-S) scale and the Global Assessment of Functioning (GAF) scale at each visit. Regarding the metabolic effects of switching to ziprasidone, weight, body mass index (BMI), waist-to-hip ratio (WHR), and lipid profile-including triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol levels-were measured at each follow-up visit. RESULTS: The BPRS scores were significantly improved at 12 weeks after switching to ziprasidone (F=5.96, df=2.11, p=0.003), whereas the CGI-S and GAF scores were not significantly changed. BMIs, WHRs, and TG levels were significantly decreased, with no significant changes in other lipid profiles. CONCLUSION: Cross-tapering switching to ziprasidone is effective for patients with schizophrenia spectrum disorders. Beyond the efficacy of the procedure, favorable metabolic profiles show that switching to ziprasidone may be helpful for maintenance therapy over an extended period.
Antipsychotic Agents
;
Body Weight
;
Cholesterol
;
Drug Therapy
;
Follow-Up Studies
;
Humans
;
Lipoproteins
;
Metabolome
;
Psychotic Disorders*
;
Schizophrenia*
;
Triglycerides
;
Waist-Hip Ratio

Result Analysis
Print
Save
E-mail